Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lilly’s Taltz superior to Humira in late-stage PsA study

Eli Lilly and Co. said the company’s psoriatic arthritis (PsA) drug Taltz was found to be more effective than the world’s best-selling prescription medicine, AbbVie Inc.’s Humira, in a late-stage study.

Read More »

J&J says its psoriasis drug superior to Novartis’ in study

Johnson & Johnson said the company’s drug Tremfya was more effective than Novartis AG’s rival medicine Cosentyx, and met the main goal of a late-stage study in adults with moderate-to-severe plaque psoriasis.

Read More »

Celgene Announces Phase 3 STYLE Study Of Otezla In Moderate-To-Severe Scalp Psoriasis Met Primary Endpoint

Celgene Corporation announced results from the phase 3 STYLE study, which showed that Otezla (apremilast) 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment response at week 16 compared with placebo.

Read More »

Bausch Health’s plaque psoriasis lotion gets tentative FDA approval

Bausch Health, formerly Valeant Pharmaceuticals, received tentative U.S. approval to market the plaque psoriasis lotion Bryhali.

Read More »

Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz and Tremfya in Patients with Moderate-to-Severe Plaque Psoriasis

Eli Lilly and Company announced today the initiation of the IXORA-R head-to-head clinical trial, designed to evaluate superiority between Taltz (ixekizumab) and Tremfya (guselkumab) in adult patients with moderate-to-severe plaque psoriasis.

Read More »

Dermavant Bags GSK Phase III-Ready Psoriasis Treatment in $330 Million Deal

Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.

Read More »

FDA declines to approve Valeant’s plaque psoriasis lotion

Valeant Pharmaceuticals International Inc.’s plaque psoriasis treatment did not get approval from U.S. health regulators.

Read More »

Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod

Novartis’ generics unit won a European panel’s recommendation for its biosimilar version of AbbVie’s Humira as the Swiss drugmaker aims to take a bite out of sales of the world’s best-selling medicine.

Read More »

Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis

Valeant Pharmaceuticals International Inc. announced that its subsidiary entered into an exclusive license agreement with Kaken Pharmaceutical Co. Ltd. to develop and commercialize products containing a new chemical entity, KP-470, which is an investigational compound for the topical treatment of psoriasis.

Read More »

Novartis Receives FDA Approval for Cosentyx Label Update to Include Moderate to Severe Scalp Psoriasis

Novartis announced that the U.S. Food and Drug Administration approved a label update for Cosentyx (secukinumab), the first interleukin-17A antagonist cleared to treat moderate to severe plaque psoriasis, to include data in moderate to severe scalp psoriasis.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom